Evolus, Inc. (EOLS) has a MoatMap StockRank of 57/100 based on Quality (39/100), Value (54/100), and Momentum (50/100) factor scores. The current signal is HOLD. Evolus is a pure-play aesthetics company commercializing Jeuveau (a botulinum toxin). While it has decent growth, it operates in a highly competitive market dominated by AbbVie (Botox) and lacks a powerful macro tailwind or structural cost advantage.
Evolus, Inc. is a medical aesthetics company dedicated to developing and commercializing innovative neurotoxins and dermal fillers. The company's flagship product, Jeuveau® (known as Nuceiva® in certain international markets), is a botulinum toxin type A designed for the temporary improvement of moderate to severe frown lines. It distinguishes itself through a focused commercial strategy and competitive product profile, aiming to capture significant market share in the rapidly growing global aesthetics market.
| Price | $6.70 |
| Market Cap | $433M |
| P/E (Forward) | 24.75 |
| Price/Book | -15.10 |
| Return on Invested Capital | -20.8% |
| Gross Margin | 66.1% |
| Operating Margin | -9.4% |
| Revenue Growth | 6.7% |
| Free Cash Flow | $-23M |
Evolus, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).